# VK2809

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/VK2809
> Markdown URL: https://mediated.wiki/source/VK2809.md
> Source: https://en.wikipedia.org/wiki/VK2809
> Source revision: 1331624658
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|Chemical compound}}
{{Infobox drug
| drug_name         =
| INN               =
| type              = <!-- empty -->
| image             = VK2809.svg
| image_class       = skin-invert-image
| alt               =
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         =
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet            =
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        =
<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  =
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 -->
| legal_BR_comment  =
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  =
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  =
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  =
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  =
| legal_US          = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment  =
| legal_EU          =
| legal_EU_comment  =
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  =
| legal_status      = <!-- For countries not listed above -->
<!-- Pharmacokinetic data -->
| bioavailability   =
| protein_bound     =
| metabolism        =
| metabolites       =
| onset             =
| elimination_half-life =
| duration_of_action=
| excretion         =
<!-- Identifiers -->
| synonyms          = VK-2809; MB07811
| CAS_number        = 852948-13-1
| UNII              = 3Z11398FNQ
| PubChem           =
| DrugBank          = DB15137
<!-- Chemical and physical data -->
| IUPAC_name        = (2''R'',4''S'')-4-(3-Chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2λ<sup>5</sup>-dioxaphosphinan-2-one
| C=28 | H=32 | Cl=1 | O=5 | P=1
}}

'''VK2809''' (formerly known as '''MB07811''') is a [thyromimetic](/source/thyromimetic) [prodrug](/source/prodrug) whose active form is selective for the [THR-β](/source/THR-%CE%B2) isoform. It is being developed by [Viking Therapeutics](/source/Viking_Therapeutics) in a phase II trial for the treatment of [nonalcoholic steatohepatitis](/source/nonalcoholic_steatohepatitis)<ref>{{Cite web |title=VK2809 |url=https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2809/ |access-date=15 September 2023 |website=Viking Therapeutics}}</ref><ref>{{Cite journal |last=Alkhouri |first=Naim |date=1 February 2020 |title=Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) |journal=Expert Opinion on Investigational Drugs |language=en |volume=29 |issue=2 |pages=99–101 |doi=10.1080/13543784.2020.1708899 |issn=1354-3784 |doi-access=free|pmid=31868036 }}</ref> and is also being investigated for [glycogen storage disease type I](/source/glycogen_storage_disease_type_I)a.<ref>{{Cite journal |last1=Zhou |first1=Jin |last2=Waskowicz |first2=Lauren R. |last3=Lim |first3=Andrea |last4=Liao |first4=Xiao-Hui |last5=Lian |first5=Brian |last6=Masamune |first6=Hiroko |last7=Refetoff |first7=Samuel |last8=Tran |first8=Brian |last9=Koeberl |first9=Dwight D. |last10=Yen |first10=Paul M. |date=1 August 2019 |title=A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia |journal=Thyroid |volume=29 |issue=8 |pages=1158–1167 |doi=10.1089/thy.2019.0007 |issn=1050-7256 |pmc=6707038 |pmid=31337282}}</ref>

In 2023, Viking Therapeutics filed a lawsuit against the developer of [ASC41](/source/ASC41), Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.<ref>{{cite news |title=Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache |url=https://www.fiercebiotech.com/biotech/viking-accuses-chinese-biotech-ruse-raid-trade-secrets-and-make-nash-cache |access-date=2 December 2023 |work=Fierce Biotech |date=3 January 2023}}</ref><ref>{{cite news | url = https://cen.acs.org/pharmaceuticals/drug-development/Viking-Therapeutics-accuses-competitor-pilfering/101/web/2023/01 | title =  Viking Therapeutics accuses competitor of pilfering proprietary information | date = January 9, 2023 | publisher = [Chemical & Engineering News](/source/Chemical_%26_Engineering_News) | quote = Viking infers that ASC41 is Ascletis’s version of—if not the same compound as—VK2809 }}</ref>

==References==
{{reflist}}

{{Thyroid hormone receptor modulators}}

Category:Thyroid hormone receptor beta agonists
Category:Prodrugs
Category:Dioxaphosphorinanes
Category:Phenols
Category:3-Chlorophenyl compounds
Category:Isopropyl compounds
Category:Experimental drugs developed for non-alcoholic fatty liver disease

---
Adapted from the Wikipedia article [VK2809](https://en.wikipedia.org/wiki/VK2809) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/VK2809?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.